INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders

Loading...
Loading...

NEW YORK, July 06, 2018 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") KERX stock prior to June 28, 2018.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. ("Akebia") AKBA. Under the terms of the transaction, Keryx shareholders will receive 0.37433 common shares of Akebia for each share of Keryx they own. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/keryx-biopharmaceuticals-inc-2

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Keryx breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Akebia is underpaying for Keryx shares, thus unlawfully harming Keryx shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Loading...
Loading...
Posted In: NewsLegalPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...